In cancer, alterations of EZH2 include gain- or loss-of-function gene mutations, overexpression of the EZH2 protein, and mutations of the H3K27 demethylase gene UTX or the SWI/SNF (INI1, SMARCA4, or SMARCA2) chromatin-remodeling complex. The gene discussed is EZH2; the disease is cancer.